{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:43:34Z","timestamp":1792417414607,"version":"4.4.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"vor","delay-in-days":95,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P20GM113131"],"award-info":[{"award-number":["P20GM113131"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Merkel cell carcinoma (MCC) is the primary cutaneous neuroendocrine carcinoma with a mortality rate higher than that of melanoma and other common skin cancers. In the United States, most cases of MCC are positive for Merkel cell polyomavirus (MCPyV), in which the viral small T antigen (ST) recruits the Tip60-EP400 chromatin remodeling complex to L-Myc, a MYC family protein with oncogenic properties. This complex initiates MYC-dependent transcriptional programs that induce replication stress. Given that ATR-CHK1 is crucial for responding to replication stress and maintaining genomic integrity, we investigated whether this ST-driven L-Myc\/Tip60-EP400 program is associated with heightened reliance on ATR-CHK1 signaling in MCPyV\n                    <jats:sup>+<\/jats:sup>\n                    \u2009MCC. Here, we demonstrate that MCPyV\n                    <jats:sup>+<\/jats:sup>\n                    \u2009MCC cells exhibit a pronounced dependency on the ATR-CHK1 pathway and that combining CHK1 inhibition with the replication-blocking chemotherapeutic agent gemcitabine produces synergistic antiproliferative effects. In MCPyV\n                    <jats:sup>+<\/jats:sup>\n                    \u2009MCC cell lines, the gemcitabine-CHK1 inhibitor combination markedly reduced cell viability and increased DNA damage and apoptosis compared to either agent alone. Conversely, in MCPyV\n                    <jats:sup>\u2212<\/jats:sup>\n                    \u2009cell lines, combination responses and apoptotic induction were attenuated, although some sensitivity to CHK1 inhibition alone was observed. These findings support ATR-CHK1 signaling as a candidate therapeutic vulnerability in MCPyV\n                    <jats:sup>+<\/jats:sup>\n                    \u2009MCC and provide a rationale for further preclinical and translational evaluation of ATR or CHK1 inhibitors in combination with gemcitabine in this virally driven cancer.\n                  <\/jats:p>","DOI":"10.1186\/s12885-026-16505-1","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:37:38Z","timestamp":1784162258000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Inhibition of the ATR-CHK1 signaling pathway sensitizes MCPyV-positive Merkel cell carcinoma to gemcitabine"],"prefix":"10.1186","volume":"26","author":[{"given":"Evelyn V.","family":"Proctor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherine F.","family":"Elsawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah R.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwei","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"issue":"5","key":"16505_CR1","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.jaad.2010.02.056","volume":"63","author":"BD Lemos","year":"2010","unstructured":"Lemos BD, Storer BE, Iyer JG, Phillips JL, Bichakjian CK, Fang LC, et al. Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system. J Am Acad Dermatol. 2010;63(5):751\u201361.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"16505_CR2","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/jid.2012.388","volume":"133","author":"KG Paulson","year":"2013","unstructured":"Paulson KG, Iyer JG, Blom A, Warton EM, Sokil M, Yelistratova L, et al. Systemic immune suppression predicts diminished Merkel cell carcinoma-specific survival independent of stage. J Invest Dermatol. 2013;133(3):642\u20136.","journal-title":"J Invest Dermatol"},{"key":"16505_CR3","doi-asserted-by":"publisher","unstructured":"Zwijnenburg EM, Lubeek SFK, Werner JEM, Amir AL, Weijs WLJ, Takes RP, Pegge SAH, van Herpen CML, Adema GJ, Kaanders J. Merkel Cell Carcinoma: New Trends. Cancers (Basel). 2021;13(7):1614. https:\/\/doi.org\/10.3390\/cancers13071614.","DOI":"10.3390\/cancers13071614"},{"key":"16505_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.77","volume":"3","author":"JC Becker","year":"2017","unstructured":"Becker JC, Stang A, DeCaprio JA, Cerroni L, Lebbe C, Veness M, et al. Merkel cell carcinoma. Nat Rev Dis Primers. 2017;3:17077.","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"16505_CR5","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.jaad.2007.11.020","volume":"58","author":"M Heath","year":"2008","unstructured":"Heath M, Jaimes N, Lemos B, Mostaghimi A, Wang LC, Penas PF, et al. Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features. J Am Acad Dermatol. 2008;58(3):375\u201381.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"16505_CR6","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jaad.2017.02.015","volume":"77","author":"DA Gunaratne","year":"2017","unstructured":"Gunaratne DA, Howle JR, Veness MJ. Definitive radiotherapy for Merkel cell carcinoma confers clinically meaningful in-field locoregional control: a review and analysis of the literature. J Am Acad Dermatol. 2017;77(1):142-148 e141.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"16505_CR7","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1002\/cam4.815","volume":"5","author":"JG Iyer","year":"2016","unstructured":"Iyer JG, Blom A, Doumani R, Lewis C, Tarabadkar ES, Anderson A, et al. Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma. Cancer Med. 2016;5(9):2294\u2013301.","journal-title":"Cancer Med"},{"issue":"9","key":"16505_CR8","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1200\/JCO.18.01896","volume":"37","author":"P Nghiem","year":"2019","unstructured":"Nghiem P, Bhatia S, Lipson EJ, Sharfman WH, Kudchadkar RR, Brohl AS, et al. Durable tumor regression and overall survival in patients with advanced Merkel cell carcinoma receiving pembrolizumab as first-line therapy. J Clin Oncol. 2019;37(9):693\u2013702.","journal-title":"J Clin Oncol"},{"issue":"1","key":"16505_CR9","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1186\/s12885-024-13129-1","volume":"24","author":"FCA de Moraes","year":"2024","unstructured":"de Moraes FCA, Kreuz M, de Lara ICA, Lobo AOM, Burbano RMR. Efficacy and safety of PD-1\/PD-L1 inhibitors in patients with Merkel Cell Carcinoma: a systematic review and Meta-analysis. BMC Cancer. 2024;24(1):1357.","journal-title":"BMC Cancer"},{"issue":"1","key":"16505_CR10","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13073-020-00727-4","volume":"12","author":"GJ Starrett","year":"2020","unstructured":"Starrett GJ, Thakuria M, Chen T, Marcelus C, Cheng J, Nomburg J, et al. Clinical and molecular characterization of virus-positive and virus-negative Merkel cell carcinoma. Genome Med. 2020;12(1):30.","journal-title":"Genome Med"},{"issue":"1","key":"16505_CR11","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jcv.2013.06.004","volume":"58","author":"C Martel-Jantin","year":"2013","unstructured":"Martel-Jantin C, Pedergnana V, Nicol JT, Leblond V, Tregouet DA, Tortevoye P, et al. Merkel cell polyomavirus infection occurs during early childhood and is transmitted between siblings. J Clin Virol. 2013;58(1):288\u201391.","journal-title":"J Clin Virol"},{"issue":"8","key":"16505_CR12","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.3201\/eid1708.110079","volume":"17","author":"YL Tolstov","year":"2011","unstructured":"Tolstov YL, Knauer A, Chen JG, Kensler TW, Kingsley LA, Moore PS, et al. Asymptomatic primary Merkel cell polyomavirus infection among adults. Emerg Infect Dis. 2011;17(8):1371\u201380.","journal-title":"Emerg Infect Dis"},{"issue":"5866","key":"16505_CR13","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1126\/science.1152586","volume":"319","author":"H Feng","year":"2008","unstructured":"Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science. 2008;319(5866):1096\u2013100.","journal-title":"Science"},{"issue":"8","key":"16505_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1008562","volume":"16","author":"M Czech-Sioli","year":"2020","unstructured":"Czech-Sioli M, Gunther T, Therre M, Spohn M, Indenbirken D, Theiss J, et al. High-resolution analysis of Merkel cell polyomavirus in Merkel cell carcinoma reveals distinct integration patterns and suggests NHEJ and MMBIR as underlying mechanisms. PLoS Pathog. 2020;16(8):e1008562.","journal-title":"PLoS Pathog"},{"issue":"3","key":"16505_CR15","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.3390\/cancers6031328","volume":"6","author":"JE Ma","year":"2014","unstructured":"Ma JE, Brewer JD. Merkel cell carcinoma in immunosuppressed patients. Cancers (Basel). 2014;6(3):1328\u201350.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"16505_CR16","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.3390\/cancers6031267","volume":"6","author":"G Stakaityte","year":"2014","unstructured":"Stakaityte G, Wood JJ, Knight LM, Abdul-Sada H, Adzahar NS, Nwogu N, et al. Merkel cell polyomavirus: molecular insights into the most recently discovered human tumour virus. Cancers (Basel). 2014;6(3):1267\u201397.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"16505_CR17","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.18632\/oncotarget.6494","volume":"7","author":"G Goh","year":"2016","unstructured":"Goh G, Walradt T, Markarov V, Blom A, Riaz N, Doumani R, et al. Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy. Oncotarget. 2016;7(3):3403\u201315.","journal-title":"Oncotarget"},{"key":"16505_CR18","doi-asserted-by":"crossref","unstructured":"Rotondo JC, Mazziotta C, Lanzillotti C, Tognon M, Martini F. Epigenetic Dysregulations in Merkel Cell Polyomavirus-Driven Merkel Cell Carcinoma. Int J Mol Sci. 2021;22(21):11464.","DOI":"10.3390\/ijms222111464"},{"issue":"10","key":"16505_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006668","volume":"13","author":"J Cheng","year":"2017","unstructured":"Cheng J, Park DE, Berrios C, White EA, Arora R, Yoon R, et al. Merkel cell polyomavirus recruits MYCL to the EP400 complex to promote oncogenesis. PLoS Pathog. 2017;13(10):e1006668.","journal-title":"PLoS Pathog"},{"issue":"5","key":"16505_CR20","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/jid.2014.446","volume":"135","author":"ME Verhaegen","year":"2015","unstructured":"Verhaegen ME, Mangelberger D, Harms PW, Vozheiko TD, Weick JW, Wilbert DM, et al. Merkel cell polyomavirus small T antigen is oncogenic in transgenic mice. J Invest Dermatol. 2015;135(5):1415\u201324.","journal-title":"J Invest Dermatol"},{"issue":"11","key":"16505_CR21","doi-asserted-by":"publisher","first-page":"6118","DOI":"10.1128\/JVI.00385-13","volume":"87","author":"J Cheng","year":"2013","unstructured":"Cheng J, Rozenblatt-Rosen O, Paulson KG, Nghiem P, DeCaprio JA. Merkel cell polyomavirus large T antigen has growth-promoting and inhibitory activities. J Virol. 2013;87(11):6118\u201326.","journal-title":"J Virol"},{"issue":"1","key":"16505_CR22","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1007\/s12672-025-02651-8","volume":"16","author":"S Passerini","year":"2025","unstructured":"Passerini S, Fracella M, Ferlosio A, Moens U, Scagnolari C, Antonelli G, et al. Investigation of mRNA expression levels of DNA damage response genes in Merkel Cell Polyomavirus-positive Merkel Cell Carcinoma: a pilot study. Discov Oncol. 2025;16(1):852.","journal-title":"Discov Oncol"},{"issue":"3","key":"16505_CR23","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.radonc.2017.09.043","volume":"126","author":"Z Qiu","year":"2018","unstructured":"Qiu Z, Oleinick NL, Zhang J. ATR\/CHK1 inhibitors and cancer therapy. Radiother Oncol. 2018;126(3):450\u201364.","journal-title":"Radiother Oncol"},{"key":"16505_CR24","doi-asserted-by":"crossref","unstructured":"Sokka M, Koalick D, Hemmerich P, Syvaoja JE, Pospiech H. The ATR-Activation Domain of TopBP1 Is Required for the Suppression of Origin Firing during the S Phase. Int J Mol Sci. 2018;19(8):2376.","DOI":"10.3390\/ijms19082376"},{"issue":"6","key":"16505_CR25","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.molcel.2015.07.029","volume":"59","author":"R Buisson","year":"2015","unstructured":"Buisson R, Boisvert JL, Benes CH, Zou L. Distinct but concerted roles of ATR, DNA-PK, and Chk1 in countering replication stress during S phase. Mol Cell. 2015;59(6):1011\u201324.","journal-title":"Mol Cell"},{"issue":"1","key":"16505_CR26","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/ncb2897","volume":"16","author":"MK Zeman","year":"2014","unstructured":"Zeman MK, Cimprich KA. Causes and consequences of replication stress. Nat Cell Biol. 2014;16(1):2\u20139.","journal-title":"Nat Cell Biol"},{"key":"16505_CR27","doi-asserted-by":"crossref","unstructured":"Carusillo A, Mussolino C. DNA Damage: From Threat to Treatment. Cells. 2020;9(7):1665.","DOI":"10.3390\/cells9071665"},{"issue":"2","key":"16505_CR28","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.molcel.2016.12.007","volume":"65","author":"R Buisson","year":"2017","unstructured":"Buisson R, Niraj J, Rodrigue A, Ho CK, Kreuzer J, Foo TK, et al. Coupling of homologous recombination and the checkpoint by ATR. Mol Cell. 2017;65(2):336\u201346.","journal-title":"Mol Cell"},{"key":"16505_CR29","doi-asserted-by":"crossref","unstructured":"Wang M, Chen S, Ao D: Targeting DNA repair pathway in cancer: Mechanisms and clinical application. MedComm (2020). 2021;2(4):654\u2013691.","DOI":"10.1002\/mco2.103"},{"issue":"23","key":"16505_CR30","doi-asserted-by":"publisher","first-page":"38022","DOI":"10.18632\/oncotarget.16723","volume":"8","author":"R Bayat Mokhtari","year":"2017","unstructured":"Bayat Mokhtari R, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B, et al. Combination therapy in combating cancer. Oncotarget. 2017;8(23):38022\u201343.","journal-title":"Oncotarget"},{"issue":"17","key":"16505_CR31","doi-asserted-by":"publisher","first-page":"4898","DOI":"10.1158\/1078-0432.CCR-21-1010","volume":"27","author":"Z Tang","year":"2021","unstructured":"Tang Z, Pilie PG, Geng C, Manyam GC, Yang G, Park S, et al. ATR inhibition induces CDK1-SPOP signaling and enhances anti-PD-L1 cytotoxicity in prostate cancer. Clin Cancer Res. 2021;27(17):4898\u2013909.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"16505_CR32","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1158\/1535-7163.MCT-06-0633","volume":"6","author":"B Ewald","year":"2007","unstructured":"Ewald B, Sampath D, Plunkett W. H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation. Mol Cancer Ther. 2007;6(4):1239\u201348.","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"16505_CR33","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/s44320-025-00085-6","volume":"21","author":"S Hofer","year":"2025","unstructured":"Hofer S, Frasch L, Brajkovic S, Putzker K, Lewis J, Schurmann H, et al. Gemcitabine and ATR inhibitors synergize to kill PDAC cells by blocking DNA damage response. Mol Syst Biol. 2025;21(3):231\u201353.","journal-title":"Mol Syst Biol"},{"issue":"1","key":"16505_CR34","doi-asserted-by":"publisher","first-page":"5574","DOI":"10.1038\/s41467-021-25904-w","volume":"12","author":"PA Konstantinopoulos","year":"2021","unstructured":"Konstantinopoulos PA, da Costa A, Gulhan D, Lee EK, Cheng SC, Hendrickson AEW, et al. A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer. Nat Commun. 2021;12(1):5574.","journal-title":"Nat Commun"},{"issue":"9","key":"16505_CR35","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1200\/JCO.2014.57.5027","volume":"33","author":"AI Daud","year":"2015","unstructured":"Daud AI, Ashworth MT, Strosberg J, Goldman JW, Mendelson D, Springett G, et al. Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors. J Clin Oncol. 2015;33(9):1060\u20136.","journal-title":"J Clin Oncol"},{"key":"16505_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-13-604","volume":"13","author":"R Montano","year":"2013","unstructured":"Montano R, Thompson R, Chung I, Hou H, Khan N, Eastman A. Sensitization of human cancer cells to gemcitabine by the Chk1 inhibitor MK-8776: cell cycle perturbation and impact of administration schedule in vitro and in vivo. BMC Cancer. 2013;13:604.","journal-title":"BMC Cancer"},{"issue":"6","key":"16505_CR37","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1038\/jid.2008.365","volume":"129","author":"KG Paulson","year":"2009","unstructured":"Paulson KG, Lemos BD, Feng B, Jaimes N, Penas PF, Bi X, et al. Array-CGH reveals recurrent genomic changes in Merkel cell carcinoma including amplification of L-Myc. J Invest Dermatol. 2009;129(6):1547\u201355.","journal-title":"J Invest Dermatol"},{"key":"16505_CR38","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.01557","volume":"2","author":"PB Chen","year":"2013","unstructured":"Chen PB, Hung JH, Hickman TL, Coles AH, Carey JF, Weng Z, et al. Hdac6 regulates Tip60-p400 function in stem cells. Elife. 2013;2:e01557.","journal-title":"Elife"},{"issue":"1","key":"16505_CR39","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.cell.2008.05.031","volume":"134","author":"TG Fazzio","year":"2008","unstructured":"Fazzio TG, Huff JT, Panning B. An RNAi screen of chromatin proteins identifies Tip60-p400 as a regulator of embryonic stem cell identity. Cell. 2008;134(1):162\u201374.","journal-title":"Cell"},{"issue":"1","key":"16505_CR40","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13072-025-00603-8","volume":"18","author":"MV Santopietro","year":"2025","unstructured":"Santopietro MV, Ferreri D, Prozzillo Y, Dimitri P, Messina G. The multitalented TIP60 chromatin remodeling complex: wearing many hats in epigenetic regulation, cell division and diseases. Epigenetics Chromatin. 2025;18(1):40.","journal-title":"Epigenetics Chromatin"},{"key":"16505_CR41","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13072-015-0039-z","volume":"8","author":"S Ravens","year":"2015","unstructured":"Ravens S, Yu C, Ye T, Stierle M, Tora L. Tip60 complex binds to active Pol II promoters and a subset of enhancers and co-regulates the c-Myc network in mouse embryonic stem cells. Epigenetics Chromatin. 2015;8:45.","journal-title":"Epigenetics Chromatin"},{"key":"16505_CR42","doi-asserted-by":"crossref","unstructured":"Curti L, Campaner S. MYC-Induced Replicative Stress: A Double-Edged Sword for Cancer Development and Treatment. Int J Mol Sci. 2021;22(12):6168.","DOI":"10.3390\/ijms22126168"},{"key":"16505_CR43","doi-asserted-by":"crossref","unstructured":"Dominguez-Sola D, Gautier J. MYC and the control of DNA replication. Cold Spring Harb Perspect Med. 2014;4(6):a014423.","DOI":"10.1101\/cshperspect.a014423"},{"key":"16505_CR44","doi-asserted-by":"crossref","unstructured":"Sevigny JL, Proctor EV, Adams H, MacDonald ER, Thomas WK, Cheng J. Protein arginine methyltransferase 5 sustains Tip60-EP400 complex via SRSF1 in Merkel cell carcinoma. Life Sci Alliance. 2025;8(11):e202503316.","DOI":"10.26508\/lsa.202503316"},{"key":"16505_CR45","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","volume":"22","author":"TC Chou","year":"1984","unstructured":"Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27\u201355.","journal-title":"Adv Enzyme Regul"},{"issue":"2","key":"16505_CR46","doi-asserted-by":"publisher","first-page":"129","DOI":"10.2217\/epi-2020-0189","volume":"13","author":"SJ Matissek","year":"2021","unstructured":"Matissek SJ, Han W, Karbalivand M, Sayed M, Reilly BM, Mallat S, et al. Epigenetic targeting of Waldenstrom macroglobulinemia cells with BET inhibitors synergizes with BCL2 or histone deacetylase inhibition. Epigenomics. 2021;13(2):129\u201344.","journal-title":"Epigenomics"},{"key":"16505_CR47","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13578-020-0376-x","volume":"10","author":"D Menolfi","year":"2020","unstructured":"Menolfi D, Zha S. ATM, ATR and DNA-PKcs kinases-the lessons from the mouse models: inhibition not equal deletion. Cell Biosci. 2020;10:8.","journal-title":"Cell Biosci"},{"issue":"21","key":"16505_CR48","doi-asserted-by":"publisher","first-page":"10780","DOI":"10.1093\/nar\/gks849","volume":"40","author":"S Liu","year":"2012","unstructured":"Liu S, Opiyo SO, Manthey K, Glanzer JG, Ashley AK, Amerin C, et al. Distinct roles for DNA-PK, ATM and ATR in RPA phosphorylation and checkpoint activation in response to replication stress. Nucleic Acids Res. 2012;40(21):10780\u201394.","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"16505_CR49","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.jid.2024.04.034","volume":"145","author":"K Bachiri","year":"2025","unstructured":"Bachiri K, Kantar D, Laurent EMN, Gaboriaud P, Durand L, Drouin A, et al. DNA damage stress control is a truncated large T antigen and euchromatic histone lysine methyltransferase 2-dependent central feature of Merkel cell carcinoma. J Invest Dermatol. 2025;145(2):400-410 e404.","journal-title":"J Invest Dermatol"},{"issue":"37","key":"16505_CR50","doi-asserted-by":"publisher","first-page":"13182","DOI":"10.1073\/pnas.0504211102","volume":"102","author":"Y Sun","year":"2005","unstructured":"Sun Y, Jiang X, Chen S, Fernandes N, Price BD. A role for the Tip60 histone acetyltransferase in the acetylation and activation of ATM. Proc Natl Acad Sci U S A. 2005;102(37):13182\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"16_suppl","key":"16505_CR51","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS9598","volume":"43","author":"R Bhakuni","year":"2025","unstructured":"Bhakuni R, Hall ET, Ansstas G, Bhatia S, Brohl AS, Burgess MA, et al. The MATRiX trial: a multicenter, randomized, phase II study of ATR inhibition (via tuvusertib) with or without avelumab in patients with advanced anti-PD-(L)1-refractory Merkel cell carcinoma. J Clin Oncol. 2025;43(16_suppl):TPS9598.","journal-title":"J Clin Oncol"},{"issue":"6","key":"16505_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2025.112567","volume":"28","author":"JL Schnabel","year":"2025","unstructured":"Schnabel JL, Frost TC, Wang AC, Ananthapadmanabhan V, Gurram S, Soroko KM, et al. IMPDH inhibition induces DNA replication stress and ATR sensitivity in Merkel cell carcinoma. iScience. 2025;28(6):112567.","journal-title":"iScience"},{"issue":"1","key":"16505_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00280-016-3003-0","volume":"78","author":"J Ciccolini","year":"2016","unstructured":"Ciccolini J, Serdjebi C, Peters GJ, Giovannetti E. Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective. Cancer Chemother Pharmacol. 2016;78(1):1\u201312.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"16505_CR54","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1200\/JCO.1991.9.3.491","volume":"9","author":"JL Abbruzzese","year":"1991","unstructured":"Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol. 1991;9(3):491\u20138.","journal-title":"J Clin Oncol"},{"issue":"8","key":"16505_CR55","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1158\/1535-7163.MCT-18-0010","volume":"17","author":"Y Wallez","year":"2018","unstructured":"Wallez Y, Dunlop CR, Johnson TI, Koh SB, Fornari C, Yates JWT, et al. The ATR inhibitor AZD6738 synergizes with gemcitabine in vitro and in vivo to induce pancreatic ductal adenocarcinoma regression. Mol Cancer Ther. 2018;17(8):1670\u201382.","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"16505_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2012.181","volume":"3","author":"E Fokas","year":"2012","unstructured":"Fokas E, Prevo R, Pollard JR, Reaper PM, Charlton PA, Cornelissen B, et al. Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation. Cell Death Dis. 2012;3(12):e441.","journal-title":"Cell Death Dis"},{"issue":"7","key":"16505_CR57","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1002\/1878-0261.12497","volume":"13","author":"ZY Oo","year":"2019","unstructured":"Oo ZY, Proctor M, Stevenson AJ, Nazareth D, Fernando M, Daignault SM, et al. Combined use of subclinical hydroxyurea and CHK1 inhibitor effectively controls melanoma and lung cancer progression, with reduced normal tissue toxicity compared to gemcitabine. Mol Oncol. 2019;13(7):1503\u201318.","journal-title":"Mol Oncol"},{"key":"16505_CR58","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.990401","volume":"13","author":"L Huang","year":"2022","unstructured":"Huang L, Ye Q, Lan C, Wang X, Zhu Y. AZD6738 inhibits fibrotic response of conjunctival fibroblasts by regulating checkpoint kinase 1\/P53 and PI3K\/AKT pathways. Front Pharmacol. 2022;13:990401.","journal-title":"Front Pharmacol"},{"issue":"2","key":"16505_CR59","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1001\/jamadermatol.2023.5362","volume":"160","author":"N Mohsin","year":"2024","unstructured":"Mohsin N, Hunt D, Yan J, Jabbour AJ, Nghiem P, Choi J, et al. Genetic risk factors for early-onset Merkel cell carcinoma. JAMA Dermatol. 2024;160(2):172\u20138.","journal-title":"JAMA Dermatol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16505-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16505-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16505-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:03:47Z","timestamp":1792415027000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16505-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16505"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16505-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]},"assertion":[{"value":"25 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. No new human samples were collected for this study; all experiments used established cell lines obtained from the sources described in the Materials and Methods.","order":1,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1244"}}